About US
Contact us
-
GSK tees up AstraZeneca rivalry with positive Jemperli-Zejula readout in endometrial cancerOn a missionto grow in oncology, GSK has more positive data to report in endometrial cancer. This time, the company is touting results for itsPD-1 inhibitor Jemperli and PARP inhibitor Zejula, which2023/12/19
-
Charles River snags clearance to produce Vertex and CRISPR's Casgevy from Tennessee plantFollowing a string of approvals in the United States and beyond, Vertex Pharmaceuticals continues to build out its manufacturing network for the world’s first CRISPR-based genetherapy, Casgevy. Monda2023/12/14
-
Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancerThe combination therapy was hailed with astanding ovationin October at the European Society for Medical Oncology (ESMO) conference in Madrid. Less than two months later, the FDA has added its acclaim2023/12/14
-
Bristol Myers Squibb's Opdualag comes up short in late-stage colorectal cancer trialBristol Myers Squibb’s PD-1/LAG3 combo Opdualag has more than proved its worth in melanoma since its first-in-class approval in 2022. Now, the drug's first venture outsidethe melanoma arena has come2023/12/12
-
After Xiidra deal with Bausch, Novartis divests Indian eye care brands to J.B. Pharma for $116MLast year, reports surfaced that Novartis—hot off the heels of a planned restructuring and spinoff of generics giant Sandoz—was further weighing a sale for its ophthalmology business. Now, after a si2023/12/12
-
UPDATED: As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growthAs Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs. Together, those2023/12/8
-
In letter to lawmakers, cancer patient advocates call for more action in fighting drug shortagesAs the year comes to a close, shortages of key cancer drugs have no end in sight. Joining the effort to push legislators to respond, the American Cancer Society Cancer Action Network (ACS CAN) illust2023/12/8
-
Pfizer site in Connecticut in line for layoffs amid $3.5B cost-cutting campaignWith layoffs hitting employees on both sides of the Atlantic, Pfizer’s $3.5 billion cost-cutting spree has kicked it into high gear this month. Now, the company’s Groton, Connecticut, site is the lat2023/12/5
-
SABCS: Handing Novartis a win, Lilly's Verzenio barely misses overall survival goal in first-line breast cancerNovartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. A phase 3 study testing Eli Lilly’s Verzeni2023/12/5
-
FDA endorses Novartis' 'pipeline in a pill,' granting first nod for potential blockbuster FabhaltaNovartis has gained the first of what it hopes are several FDA approvals for its factor B inhibitor iptacopan,dubbedtwo months ago “a pipeline in pill,” by analysts at ODDO BHF. The United States reg2023/11/30